DEF 14A: Achieve Life Sciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Achieve Life Sciences will hold its annual stockholders meeting virtually on June 5, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Achieve Life Sciences will hold its Annual Meeting of Stockholders on June 5, 2024, at 8:00 a.m. Pacific time, as a virtual meeting.
• Stockholders of record as of April 10, 2024, are entitled to vote.
• The meeting's purposes include electing eight directors and ratifying the appointment of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board recommends voting for all director nominees and for the ratification of PwC's appointment.
• The company's Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2023, are available online.
• In May 2023, Achieve Life Sciences sold 3,000,000 shares of common stock at $5.50 per share in a registered direct offering, raising gross proceeds of $16.5 million.
• In February 2024, Achieve Life Sciences sold 13,086,151 shares of common stock at $4.585 per share in a registered direct offering and issued warrants in a concurrent private placement, raising gross proceeds of approximately $60.0 million.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, so the sentiment is neutral to slightly positive due to the company's recent capital raising activities.

Positives

• The company is making efforts to lower costs and align with sustainability goals by holding a virtual stockholder meeting.
• The company successfully raised capital through registered direct offerings and private placements in 2023 and 2024.
• The Board of Directors has established several committees to assist in performing its responsibilities, including an Audit Committee, a Compensation Committee, a Nominating and Governance Committee, and a Chemistry, Manufacturing and Controls Committee.

Negatives

• The company reported net losses of $29,815,000 in 2023, $42,350,000 in 2022 and $33,152,000 in 2021.

Risks

• The company is dependent on the successful development and commercialization of cytisinicline.
• The company's future success depends on the FDA's acceptance and approval of the New Drug Application (NDA) for cytisinicline.
• The company's compensation recovery policy enables the company to recover incentive-based compensation from current and former officers in the event of an accounting restatement resulting from material noncompliance with any financial reporting requirements under federal securities laws.

Future Outlook

The document outlines the company's upcoming annual meeting and provides information relevant to voting on key proposals, but does not offer specific forward-looking statements about the company's future financial performance or business prospects beyond the standard legal disclaimers.

Management Comments

• John Bencich, Chief Executive Officer, stated the Board of Directors recommends voting for all director nominees and for the ratification of PwC's appointment.
• The company believes that a virtual stockholder meeting provides greater access to those who may want to attend, and therefore we have chosen that the Annual Meeting be held by virtual meeting.
• This approach also lowers costs and aligns with our broader sustainability goals.

Industry Context

This announcement is typical for publicly traded companies, outlining the agenda and procedures for the annual meeting, including the election of directors and ratification of the auditor. The virtual format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is generally in line with industry practices for similarly sized biotechnology companies.
• The use of performance-based restricted stock units (PSUs) tied to the achievement of clinical and regulatory milestones is a common practice in the biotechnology industry to align executive compensation with company goals.
• The change of control provisions in the executive employment agreements are fairly standard, providing for severance payments and accelerated vesting of equity awards upon certain termination events.

Related Party Transactions

• John Bencich purchased 5,000 shares of common stock in the May 2023 registered direct offering.
• Contrarian Alpha, LP purchased 70,000 shares of common stock in the May 2023 registered direct offering.
• John Bencich purchased 10,000 shares of common stock and 10,000 warrants in the February 2024 registered direct offering and concurrent private placement.
• Richard Stewart purchased 10,000 shares of common stock and 10,000 warrants in the February 2024 registered direct offering and concurrent private placement.
• Contrarian Alpha, LP purchased 100,000 shares of common stock and 100,000 warrants in the February 2024 registered direct offering and concurrent private placement.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, including the election of directors and the ratification of the independent auditor.
• The outcome of the votes will influence the company's governance and financial oversight.
• The company's performance and the success of cytisinicline will impact shareholder value.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Stockholders on June 5, 2024.
• The company will continue to pursue the development and commercialization of cytisinicline.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, PricewaterhouseCoopers, Stockholders, Cytisinicline, Achieve Life Sciences